These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1247 related articles for article (PubMed ID: 24565525)
1. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525 [TBL] [Abstract][Full Text] [Related]
2. Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy. Wang S; Cao M; Deng X; Xiao X; Yin Z; Hu Q; Zhou Z; Zhang F; Zhang R; Wu Y; Sheng W; Zeng Y Adv Healthc Mater; 2015 Jan; 4(2):281-90. PubMed ID: 25044638 [TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy. Wang S; Zhang J; Wang Y; Chen M Nanomedicine; 2016 Feb; 12(2):411-20. PubMed ID: 26711968 [TBL] [Abstract][Full Text] [Related]
4. Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells. Alinejad V; Hossein Somi M; Baradaran B; Akbarzadeh P; Atyabi F; Kazerooni H; Samadi Kafil H; Aghebati Maleki L; Siah Mansouri H; Yousefi M Biomed Pharmacother; 2016 Oct; 83():229-240. PubMed ID: 27372407 [TBL] [Abstract][Full Text] [Related]
5. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin. Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431 [TBL] [Abstract][Full Text] [Related]
6. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411 [TBL] [Abstract][Full Text] [Related]
7. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer. Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224 [TBL] [Abstract][Full Text] [Related]
8. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Kastl L; Brown I; Schofield AC Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894 [TBL] [Abstract][Full Text] [Related]
9. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1. Yang G; Wu D; Zhu J; Jiang O; Shi Q; Tian J; Weng Y Oncol Rep; 2013 Aug; 30(2):877-89. PubMed ID: 23760062 [TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. Wang H; Agarwal P; Zhao S; Xu RX; Yu J; Lu X; He X Biomaterials; 2015 Dec; 72():74-89. PubMed ID: 26344365 [TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy. Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784 [TBL] [Abstract][Full Text] [Related]
12. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. O'Brien K; Lowry MC; Corcoran C; Martinez VG; Daly M; Rani S; Gallagher WM; Radomski MW; MacLeod RA; O'Driscoll L Oncotarget; 2015 Oct; 6(32):32774-89. PubMed ID: 26416415 [TBL] [Abstract][Full Text] [Related]
13. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion. Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184 [No Abstract] [Full Text] [Related]
14. Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. Shi S; Han L; Deng L; Zhang Y; Shen H; Gong T; Zhang Z; Sun X J Control Release; 2014 Nov; 194():228-37. PubMed ID: 25220161 [TBL] [Abstract][Full Text] [Related]
15. Interconnected hyaluronic acid derivative-based nanoparticles for anticancer drug delivery. Park JH; Cho HJ; Termsarasab U; Lee JY; Ko SH; Shim JS; Yoon IS; Kim DD Colloids Surf B Biointerfaces; 2014 Sep; 121():380-7. PubMed ID: 24993066 [TBL] [Abstract][Full Text] [Related]
16. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy. Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789 [TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles. Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763 [TBL] [Abstract][Full Text] [Related]
18. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release. Lin CW; Lu KY; Wang SY; Sung HW; Mi FL Acta Biomater; 2016 Apr; 35():280-92. PubMed ID: 26853764 [TBL] [Abstract][Full Text] [Related]
19. Co-delivery of doxorubicin and interleukin-2 via chitosan based nanoparticles for enhanced antitumor efficacy. Wu J; Tang C; Yin C Acta Biomater; 2017 Jan; 47():81-90. PubMed ID: 27729232 [TBL] [Abstract][Full Text] [Related]
20. Preparation of collagen peptide functionalized chitosan nanoparticles by ionic gelation method: An effective carrier system for encapsulation and release of doxorubicin for cancer drug delivery. Anandhakumar S; Krishnamoorthy G; Ramkumar KM; Raichur AM Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):378-385. PubMed ID: 27770906 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]